What's Happening?
A recent Gallup poll indicates that approximately 11% of Americans are currently using GLP-1 medications for weight loss. This marks a significant increase over the past two years, coinciding with a decline in the national obesity rate. The obesity rate in the U.S.
has decreased to 36.4% in 2026, down from a record high of 39.9% in 2022. The rise in GLP-1 drug usage follows the FDA's approval of Wegovy, a GLP-1 medication, for weight loss treatment in 2021. The poll also highlights that 68% of users are taking brand-name drugs from companies like Novo Nordisk and Eli Lilly, while 19% are using custom-mixed drugs not approved by the FDA. Public awareness of these medications has increased, with 91% of respondents in 2026 acknowledging their use for weight loss, up from 80% in 2024.
Why It's Important?
The increased use of GLP-1 medications and the corresponding decline in obesity rates could have significant implications for public health and the pharmaceutical industry. A lower obesity rate may lead to reduced healthcare costs and improved overall health outcomes for Americans. The pharmaceutical companies producing these drugs, such as Novo Nordisk and Eli Lilly, may see increased demand and profitability. However, the use of unapproved custom-mixed drugs raises concerns about safety and regulatory oversight. The growing public awareness and acceptance of these medications suggest a shift in how weight loss is approached in the U.S., potentially influencing future healthcare policies and practices.
What's Next?
As the use of GLP-1 medications continues to rise, regulatory bodies like the FDA may need to address the safety and approval of custom-mixed drugs. Pharmaceutical companies could expand their research and development efforts to create more effective weight loss treatments. Healthcare providers might also need to adapt their practices to incorporate these medications into weight management programs. Additionally, public health campaigns could focus on educating the population about the benefits and risks of GLP-1 drugs, ensuring informed decision-making among potential users.
